UK clinical-stage drug delivery company CRISM Therapeutics Corporation (AIM: CRTX) on Wednesday reported progress in its Phase 2 clinical trial of irinotecan-ChemoSeed for the treatment of glioblastoma, confirming the successful manufacture of the first clinical batch.

The batch was produced by US-based contract development and manufacturing organisation ProMed Pharma LLC in compliance with current Good Manufacturing Practice standards and will now undergo sterilisation and release testing ahead of use in the trial.

CRISM Therapeutics Corporation is continuing to work with contract research organisation Aixial and its first clinical trial site to complete final activation steps prior to initiating patient dosing. While progress is advancing, the company has extended guidance for first patient dosing to the first half of 2026, citing uncertainty over precise timing.

ChemoSeed, the company's lead product, is designed for direct implantation into tumours or resection margins to enable localised and sustained delivery of chemotherapy. In glioblastoma, the approach allows treatment to bypass the blood-brain barrier, improving drug delivery to tumour tissue.